Contract Research Organization in Argentina – New regulations.

The Ministry of Health in Argentina issued a new regulation that significantly reduces the timelines for the approval of clinical trials.
Contract Research Organization in Argentina

On April 26th, The Ministry of Health in Argentina (ANMAT) issued a new regulation that significantly reduces the timelines for the approval of clinical trials. The new regulation will accelerate the evaluation process from 160 business days to 70 days or less. With this revised legislation in place, Argentina is expecting to double the trials running in the country in the next 24 months according to Argentina’s president, Mauricio Macri. In fact, there are already strong signs regarding the impact of this new regulation that were shared by the Argentinean Chamber of Pharmaceutical Products which stated that 20 studies were approved during a recent two week time period.

Key Changes:

  • Establishes a “validation period” of 3 working days (start counting the day after the submission). Only complete packages will move forward to the evaluation process.
  • The evaluation process is expected to take 60 working days (for technical evaluation) + 10 working days (for administrative aspects): 70 working days in total for Clinical research studies.
  • The studies evaluated and approved/ongoing in countries with high vigilance standards will be approved in 45 working days (to provide technical reports) + 10 administrative working days (to issue final approval letter): 55 days in total.

Advantages of the new regulation

This is significant news for any Sponsor looking to conduct clinical trials in Latin America with Argentina being one of the key countries. We believe these new regulations and the resulting shorter timelines for evaluations make Argentina an attractive country for running clinical trials.  There are a number of advantages including:

  • A high concentration of potential trial subjects.
  • Qualified and reliable medical professionals.
  • Low drop-out rates.
  • Strong enrollment and compliance rates with low drop-out rates.
  • Quality data with excellent performance in all FDA & EMA audits.

Share:

Share on linkedin
Share on twitter
Share on facebook

More Posts

Send Us A Message